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Abstract
Background: The prevalence of High-Risk Human papilloma virus (HR-HPV), a necessary cause of invasive cervical
cancer (ICC) is relatively high in HIV infected women. Gaps exist in our knowledge of the optimal approaches for
managing women who have HR-HPV with normal cervical cytology (NCC) particularly in settings of HIV infection.
Methods: Between May 2012 and June 2013 we conducted a colposcopic assessment of HIV-infected women with
prior (NCC) and known HR-HPV status to compare cervical abnormalities in women with and without HR-HPV.
Colposcopic examinations were done at the Operation Stop Cervical Cancer (OSCC) unit of the Jos University
Teaching Hospital (JUTH), Jos, Nigeria. Abnormal colposcopic finding (ACF) was defined as areas of aceto-white
epithelium involving the squamo-coulumnar junction, areas of punctation, mosaic pattern or atypical vessels. We
compared proportions of ACF as well as histologic grades of cervical intra-epithelial neoplasia (CIN) in women with
or without HR-HPV. Statistical analysis was done on STATA.
Results: We conducted colposcopic examinations in 78 out of 89 (86.5%) eligible women. The mean age of the
cohort was 32.4 years (SD ±4.6) with a median 32 years (IQR 29–36). After a mean follow up time of 20.1 months
from the initial cervical pap cytology and HR-HPV testing, we found 12 of 78 (15.4%) women with ACF. The odds
for an ACF was statistically higher [OR = 4.0 (95% CI: 1.1-14.7)] in women with HR-HPV compared to those without.
Of the twelve women with ACF, subsequent histologic examination of colposcopically directed cervical biopsies
confirmed CIN 1 in 4 cases (33.3%), CIN 2 in 1 case (8.3%), CIN 3 in 2 cases (16.7%), carcinoma-in-situ (CIS) in 2 cases
(16.7%), and normal cervix in 3 (25.0%). Overall, the proportion of women detected with any grade of CIN was
11.5% (9/78) and 6.4% (5/78) were CIN 2 or greater lesion (CIN2+).
Conclusion: HIV-infected women with NCC and HR-HPV had a four-fold higher likelihood for an ACF. The practice
of early colposcopic examination of HIV-infected women with prior NCC and HR-HPV may increase early detection
of higher grade CIN and CIS cancer stages in our setting.
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Cervical cancer was responsible for up to 25.4% of all
new cancer cases in women in sub-Saharan Africa in
2012 [1]. Nigeria has a large burden of invasive cervical
cancer and mortality [2] is equally high due to late pres-
entation and limited treatment facilities. In Nigeria,
11,431 cases of cervical cancer and 5,952 cervical cancer
deaths were reported in 2010 compare to 5,714 cases
and 3,158 cervical cancer deaths in 1980 in the same
country [2]. The high burden of human immuno defi-
ciency virus (HIV) among women in Nigeria contributes
to the growing incidence of premalignant lesions of the
cervix as well as progression to invasive cervical cancer,
necessitating the integration of cervical screening efforts
using visual inspection with acetic acid (VIA) into exist-
ing HIV prevention, care and treatment programs in
Nigeria [3].
In developed countries of the world, well-organized
cervical cancer screening programs using Pap smear cy-
tology has led to significant declines in invasive cervical
cancer. Such national programs do not exist in most
developing countries like Nigeria. Studies have shown
that women with HIV have an increase risk of having
high grade squamous intraepithelial lesions (SILs) with
higher rates of progression to invasive stages [4,5]. Studies
on the association of SILs and degree of HIV immunosu-
pression have documented a significant risk in some and
not others [3,6,7]. The role of high-risk human papilloma
virus (HR-HPV) in cervical carcinogenesis has been well
established from epidemiologic studies [8]. Studies have
demonstrated the effectiveness of HR-HPV DNA testing
in detecting high-grade squamous intraepithelial lesions
and prevention of invasive cervical cancer cases compare
to cervical cytology [9-12]. Also, the utility of HR-HPV
DNA testing as a cervical cancer prevention strategy has
demonstrated significant reduction in cervical cancer
mortality compare to conventional Pap cytology in re-
source limited countries [13].
Additionally, studies have shown that even in settings
where cervical cancer screening is available, conven-
tional Pap cytology is associated with high false negative
and positive results [14] and some high-grade cervical
lesions have been missed in women with normal cervical
cytology reports. The Athena trial [15] and a prevalence
study in India have shown the potential benefits of
HR-HPV testing, for the detection of high-grade cervical
lesions among women with either atypical squamous
intraepithelial lesions of undetermined significance or a
negative pap smear cytology [16].
Gaps exist in the knowledge of optimal management
approaches for women with normal pap cervical cytology
and a positive HR-HPV particularly in the setting of HIV
infection. To assess the possible role of HR-HPV DNA
testing in detecting underlying high-grade cervical lesions
in women with prior NCC in the setting of HIV infection,
we conducted a pilot study of HR-HPV DNA testing in
women with NCC in a cohort of HIV infected women in
Jos, Nigeria. The prevalence and epidemiologic factors
associated with HR-HPV in our patient population have
been previously reported [17]. The current report fo-
cused on colposcopic examination findings and cervical
abnormalities in women with or without HR-HPV in
our cohort.
Methods
Study setting, study population and procedures
Between May 2012 and June 2013, we enrolled a cohort of
HIV-infected women with NCC at the Reproductive Health
Unit (RHU) of APIN of the APIN/Harvard PEPFAR HIV
Clinic, Jos University Teaching Hospital, (JUTH) Jos,
Nigeria. The RHU was set up in 2008 and is staffed by two
reproductive health nurses and a gynecologist to address is-
sues related to contraception and cervical cancer screening.
Routine care at JUTH includes CD4+ T cell (Partec,
Gemany) and viral load (Roche Amplicor 1.5, lower detec-
tion limit 400 copies/ml) measurement before antiretro-
viral therapy (ART), then approximately every 3 months
during ART. Initiation of ART follows the Nigerian
National Guidelines for HIV and AIDS treatment and
care in adolescents and adults, 2007 [18]. Other informa-
tion routinely collected in the clinical care of patients at
JUTH included the following: demographics, ART history
and co-infections (hepatitis B, hepatitis C and tubercu-
losis). At enrollment, each patient gave written informed
consent for collection and use of their medical informa-
tion for research purposes.
A detailed questionnaire was administered to each
participant to determine age, age at first coitus, parity,
duration of HIV infection, ART history, previous abor-
tions, history of contraception, previous Pap smear,
smoking and alcohol consumption. Patient information
not recalled by study participants such as duration of
HIV disease, ART history etc. were extracted from their
electronic database.
During the first part of this study, this cohort of
women had cervical samples obtained for HR-HPV diag-
nosis by Hybrid Capture 2 (HC2) signal amplification
(Digene Corporation, Gaithersburg, USA. The HC2 test
is qualitative and a positive test indicates presence of
one or more of the following 13 sub-types of HR-HPV:
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 or 68. Other
details of the enrollment setting and sampling proce-
dures for Pap smear preparation and interpretation has
been described in the preliminary published work by
Musa et al. [17]. At the time of enrollment, informed
consent was obtained for a follow up visit during which
a colposcopic examination would be done to detect any
abnormality in the cervix.
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Operation Stop Cervical Cancer (OSCC) unit of the de-
partment of Obstetrics and Gynecology, JUTH. The
study participants were contacted through phone calls
by the study nurse and a study examination visit was
scheduled. In situations where the participants were not
successfully contacted through phone calls (“wrong
numbers”, “number not available”, etc.), the researchers
made efforts to track participants at their pharmacy drug
pick-up visits where they received their regular anti-
retroviral drugs at the Adult HIV Treatment Clinic of
JUTH. The colposcopic examinations were performed
by a consultant gynecologist trained in VIA and col-
poscopic examination of the cervix. The gynecologist
conducting the colposcopic examination was blinded
to the HR-HPV status of the participant. Women who
had detectable abnormalities were treated according
to standard guidelines in our hospital. Abnormal col-
poscopic finding was defined as areas of aceto-white
epithelium involving the squamo-coulumnar junction,
areas of punctation, mosaic pattern or atypical vessels.
Unsatisfactory colposcopic examination defined situations
where the squamo-columnar junction was not clearly
visualized. A tissue biopsy forceps was used to obtain
cervical tissue as directed by the abnormal colposcopic
area. Participants with normal colposcopic findings were
reassured and booked for annual cervical pap cytology.
The biopsy specimens were immediately fixed in formalin
and transported to the histopathology laboratory for pro-
cessing and histologic examination and interpretation by a
trained pathologist who was blinded to the HR-HPV sta-
tus of the specimen. The colposcopic findings were
illustrated in a diagram and coded for subsequent entry
into the study database.
Procedure for colposcopic examination and
histopathology reporting
We used the Leisegang D-10625, Model1DS Ur Nr
55764, Colposcope, Berlin, Germany to examine the cer-
vix. Each participant was placed in lithotomy position
and an appropriate size Coscus speculum was introduced
into the vagina to expose the cervix for examination. For
each participant we first examined the vulva, vagina and
the cervix before the application of 3% acetic acid solu-
tion. Prior to application of 3% acetic acid, the cervices
seen to have excess cervical mucus were washed with
0.9% Normal saline to dislodge excess mucus discharge.
Colposcopic abnormalities were described as normal, ab-
normal or unsatisfactory. Abnormal areas were biopsied
using a punch cervical biopsy tissue forceps. The cervical
tissues were processed in the histopathology laboratory.
The Histopathologist was blinded to the HPVstatus of the
participant and interpreted processed cervical samples
either as Normal or CIN 1, CIN 2, CIN 3 or Carcinoma in
Situ (CIS) with either well-differentiated, moderate differ-
entiated or poorly differentiated squamous cell carcinoma
or other variants if applicable.
Data collection and statistical analysis
We created a study database that included routinely col-
lected demographic parameters, CD4+ cell count (Partec,
Munster, Germany), plasma HIV RNA (viral load; Roche
COBAS Amplicor HIV-1 monitor test, version 1.5; Roche
Diagnostics, GmbH, Mannheim Germany), HC2 HR-HPV
status, date of colposcopic examinations, colposcopic find-
ings and histology results (for those with colposcopic
cervical tissue biopsy). To conduct statistical analyses, the
database variables were coded for relevant statistical
analysis on STATA. All analyses were performed using
STATA version 11.0, College station, Texas, USA.
Summary statistics were generated using two-way tables
of association to compare baseline socio-demographic
characteristics of study participants with normal versus
abnormal colposcopic examination findings. The Pearson’s
chi square and/or Fisher’s exact test was performed where
applicable. We also created relevant indicator variables in
order to run univariabe logistic regression analyses to de-
termine odds ratio of having colposcopic abnormalities. In
the multivariable logistic regression model the association
between positive HR-HPVand abnormal colposcopic find-
ings was adjusted for age category ≥30 years. Because of
the relatively small numbers of participants in this pilot
data, we estimated the proportions of histologic findings
of the cervical biopsies in the study sample. All statistical
tests were reported with corresponding 95% confidence
interval and p-values. Probability estimates <0.05 were
considered statistically significant.
Human subject protection
Institutional Review Board approval was obtained from
the Harvard School of Public Health for identification
and enrollment of HIV-infected women into care, treat-
ment and other support services at APIN, JUTH. Second-
ary use of data approval was also granted by the Harvard
School of Public Health to use CD4+ T cell count, viral
load and other relevant patient data. The protocol for this
study was approved by the JUTH Human Subject Ethics
Committee.
Results
We studied 78 women out of 89 eligible participants
(86.5%) who completed colposcopic examination (Table 1).
Of the 78 HIV-infected women included in this study, 30
(38.5%) were HR-HPV positive and 48 (61.5%) were
HR-HPV negative.
Socio-demographic characteristics of the study cohort
have been summarized in Table 1. The mean age was
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29–36 years).
Colposcopic abnormalities and HR-HPV
Colposcopic examinations were performed after a mean
of 20.1 months from the initial cervical pap cytology and
HR-HPV status evaluation. The mean follow up time
between initial Pap cytology and subsequent colposcopic
evaluation was comparable for women who were posi-
tive HR-HPV (20.5 months) and those negative HR-HPV
(19.9 months); p-value 0.554. Colposcopy revealed 12 of
78 (15.4%) women with abnormal findings. The odds
ratio (OR) of having an abnormal colposcopic examin-
ation finding was 4.0 (95% CI: 1.1-14.7) in women who
were HR-HPV positive compared to HR-HPV negative;
p-value 0.039 (Table 1 and Figure 1).
Colposcopic abnormalities and histologic diagnoses of
CIN/Cancer
Of the twelve women with abnormal colposcopic find-
ings, subsequent histologic examination confirmed CIN
1 in 4 cases (33.3%), CIN 2 in 1 case (8.3%), CIN 3 in 2
cases (16.7%), carcinoma-in-situ (CIS) in 2 cases (16.7%),
and normal cervix in 3 cases (25.0%) (Table 2). In all, 5
out 12 (41.7%) of those with abnormal colposcopic find-
ings had a confirmed CIN 2 or greater lesion (CIN2+) of
the cervix. Overall, the proportion of women detected
with any grade of CIN was 11.5% (9/78) and CIN2+ was
6.4% (5/78) in our cohort. Subsequent analysis of CIN
2+ lesions detected by HR-HPV status showed that
13.3% (4/30) were detected in the HR-HPV positive
group compare to 2.1% (1/48) in the HR-HPV negative
group (P-value 0.0494).
Colposcopic abnormalities, age category and HR-HPV status
In a multivariabe logistic regression model including
age≥30 years and HR-HPV positive, we found an OR= 4.9
(95% CI: 0.91-26.2, p value 0.065) for age ≥30 years and an
OR=5.4 (95% CI: 1.4-21.5, p value 0.016) for an HR-HPV
positive woman of having an abnormal colposcopic exam-
ination finding (Table 3).
Discussion
In this pilot study, after a mean follow up time of
20.1 months, we documented abnormal colposcopic find-
ings in 12 of 78 (15.4%) HIV-infected women with prior
NCC. Women with HR-HPV had a five-fold higher likeli-
hood of an abnormal colposcopic description compare to
those without after controlling for age. We also observed
that women with positive HR-HPV had a higher propor-
tion of CIN 2+ cervical abnormalities compare to women
negative for HR-HPV. Overall, the proportion of any CIN
lesion was 11.5% (9/78) and CIN2+ was 6.4% (5/78) in our
cohort.
In a cohort study reported from India [16], the authors
described a prevalence of 10.0% of HR-HPV types 16
and 18 in women with cytologically negative Pap smear
and any CIN lesion was found in 15% (19 out of 123
women with negative pap cytology) following colposcopy
and directed biopsies. A meta-analysis of over 20 studies
showed a high prevalence of 36.3% of any HR-HPV
among HIV infected women with normal cervical cytology
[19] and HIV infected women with high-grades lesions
were significantly more likely to be infected with HPV
types 11, 18, 33, 51, 52, 53, 58 and 61. Although, the
method of HR-HPV detection in our cohort was based on
HC2 which shows positivity for any of the following
HR-HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
Table 1 Socio-demographic characteristics of HIV infected
women with normal cervical cytology who had
colposcopic follow up examination in Jos Nigeria
N=78
Variable Abnormal
findings
Normal
finding
p-value
Age (years) 34.7±5.5 32.9± 4.4 0.069 (t-test)
Parity (N=78)
0 2(18.2) 9(81.8) 0.578 (Fisher)
≥1 10(14.9) 57(85.1)
HR_HPV status
(N=78)
Positive 8(26.7) 22(73.3) 0.05 (Fisher)
Negative 4(8.3) 44(91.7)
History of previous
abortions (N=76)
Yes 6(18.2) 27(81.8) 0.616 (Pearson)
No 6(14.0) 37(86.0)
History of contraceptive
use (N=78)
Never 4(21.1) 15(78.9) 0.224 (Fisher)
Past 5(20.8) 1979.2)
Current 3(8.6) 32(91.4)
Age_Category
(N=78)
≤30 2(7.1) 26(92.9) 0.122 (Fisher)
>30 10(20.0) 40(80.0)
CD4+ cell count
category (N=78)
<350/mm
3 4(25.0) 12(75.0) 0.449 (Fisher)
≥350/mm
3 9(14.5) 53(85.5)
Viral load category
(N=78)
<400 copies/ml 11(19.0) 47(81.0) 0.498 (Fisher)
≥400 copies/ml 2(10.0) 18(90.0)
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our pilot data is comparable with the findings described
in India [16]. The India study used specific PCR primers
to detect the most common HR-HPV types 16 and 18,
which have been reported to account for 70% of cervical
cancer globally [8]. Other studies have found a similarly
high association of HIV and HR-HPV infection, but
reported a higher prevalence and association of higher
grade squamous lesions with PCR HR-HPV sub-types
52 and 58 [20]. A recent study on the burden and distri-
bution of HR-HPV types among HIV-infected women
in Western Nigeria found a comparably higher preva-
lence of HR-HPV among HIV-infected women than
negative controls with types 16, 35, 58 and 31 being the
most prevalent types [21]. Additionally, the ATHENA
trial [15], where over 1,500 women with atypical squa-
mous cells of undetermined significance (ASCUS) were
examined colposcopically and their specific HR-HPV
determined by Cobas 4800, found higher absolute risk
of detection of CIN 2+ in women with HR-HPV 16/18
compared to the detection of pooled HR-HPV positive
or HR-HPV negative women (24.4%, 14.0% and 0.8%
respectively). These findings suggest that HR-HPV testing
could increase the detection rate of SILs/Cervical cancer if
colposcopic examinations are performed on patients with
Negative HR-HPV Positive HR-HPV
12
Figure 1 Normal colposcopic (1) and abnormal colposcopic (2) examinations in HIV infected women with positive HR-HPV compare to
those negative for HR-HPV.
Table 2 Summary of main outcome for HIV infected
women with prior normal cervical cytology with positive
HR-HPV or negative HR-HPV in Jos Nigeria
Outcome Positive
HR-HPV
Negative
HR-HPV
P-value
Mean follow up time (Months) 20.5±4.1 19.9±4.3 0.554*
Colposcopic finding
Abnormal 9(29.0) 22(71.0) 0.001
†
Normal 3(6.4) 44(93.6)
Cervical biopsy taken
Yes 10(83.3) 2(16.7) 0.001
†
No 21(32.8) 43(67.2)
Histologic diagnosis
Normal cervix 1(33.3) 2(66.7)
CIN I 3(75.0) 1(25.0)
CIN II 0(0.0) 1(100.0)
CIN III 2(100.0) 0(0.0)
Cervical Carcinoma in situ (CIS) 2(100.0) 0(0.0)
Proportion of CIN 2+ detected 0.133 0.021 0.0494
‡
*Student t-test for means,
†Fisher’s exact p-values,
‡t-test of proportion.
Table 3 Univariate and multivariate logistic regression of
abnormal colposcopic examination findings in HIV
infected women with normal cervical cytology in Jos
Nigeria
Variable Odds ratio (OR) 95% CI P–Value
CD4< 350 cells/mm
3 1.03 0.30-3.48 0.968
Positive HR-HPV (HC2) 4.00 1.08-14.75 0.037
Previous abortions 0.73 0.21-2.51 0.617
Age ≥30 years 3.58 0.73-17.45 0.115
Viral load >400 RNA copies/ml 0.45 0.10-2.22 0.33
Positive HR-HPV (HC2) 5.44 (AOR) 1.37-21.50 0.016
Age ≥30 years 4.87 (AOR) 0.91-26.17 0.065
AOR = Adjusted Odds Ratio of having an abnormal colposcopic examination
findings in a model of positive HR-HPV and Age ≥30 years as co-variates
(Hosmer-Lemeshow goodness-of-fit p-value 0.782).
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lar setting.
Our pilot data showed that women who had a positive
HR-HPV had a five-fold higher likelihood of an abnormal
colposcopic examination after adjusting for age. Other fac-
tors such as CD4+ Tcell count, HIV-1 viral load, previous
abortions, and use of contraceptives were not significantly
associated with having an abnormal colposcopic examin-
ation finding. A prior study in Jos during an era when
accessibility and use of antiretroviral drugs was limited
[6], found a high prevalence of cervical dysplasia among
HIV-infected women whose CD4+ T cell count was less
than 200 cell/mm
3, high viral load (101,781 copies/ml)
and those with a clinical evidence of HPV infection on
visual inspection. A study from a Brazilian HIV-infected
cohort, found a higher association of current cigarette
smoking, CD4+ T cell count less than 350 cells/mm
3,
and HR-HPV with colposcopic/histopathologic diagno-
sis of CIN2+ lesions [22]. Studies have shown a significant
association of cervical cancer risk with cigarette smoking,
oral contraceptive use, multiparity, impaired cellular im-
munity and chronic inflammation [23]. Our small study
population undergoing successful antiretroviral therapy,
may further explain the lack of difference in colposcopic
abnormalities with CD4+ Tcell count, viral load and other
socio-demographic characteristics.
Subsequent colposcopically directed biopsy and histo-
logic diagnosis a significant difference in the proportion
of CIN 2+ lesions detected in HIV infected women who
were HR-HPV positive compare to those HR-HPV nega-
tive. These findings have implications in the practice of
cervical cancer screening in our setting. First, since col-
poscopy and directed biopsy with histologic examination
is the gold-standard for the diagnosis of CIN/or invasive
cancer; women with HR-HPVare more likely to have such
colposcopic examination and directed biopsies thereby
increasing the chances of diagnosing high-grade lesions
and/or cancer. Results of HPV genotype distribution from
meta- analysis data have shown that the HPV genotype
distribution in low grades cervical lesions differs from that
in cervical cancer [24], suggesting the need to conduct
studies on the type-specific HPV genotypes causing cer-
vical cancer in different geographic settings. Several previ-
ous studies on the role of colposcopiy in diagnosing
squamous intraepithelial lesions and cervical cancer have
reported a higher risk of detecting SILs/cancer in women
who had prior HR-HPV during follow up compared to
HR-HPV negative controls [22,25,26].
One alarming finding in our pilot study is the detec-
tion of 2 cases of CIS of the cervix following colposcopic
examination and directed biopsies in women with prior
NCC after only about 20 months of follow up. Indeed,
studies have shown an increased hazard of rapid pro-
gression from CIN to ICC stages in women infected with
HIV compared to HIV-uninfected controls [5]. This
finding suggests that women infected with HIV in our
setting may benefit from early colposcopic examination
of the cervix even when Pap smear cytology is normal.
The major strength of this study lies in the fact that
HR-HPV testing is not yet part of our screening for cer-
vical cancer in Nigeria and this is first study examining its
possible role in detecting high-grade cervical lesions par-
ticularly in HIV-infected women with NCC. We were also
able to enroll 86% of the initial cohort and conducted col-
poscopic examinations irrespective of HR-HPV status. We
must however, acknowledge the limitations of a relatively
small sample size, which may have reduced the statistical
power to control for potential confounding effects on de-
tection of CIN2+ in our cohort. We also did not perform
colposcopic examination at the time of initial Pap or
HR-HPV determination and the abnormalities/CIN lesions
detected at follow up colposcopy examinations may have
existed at the time of initial Pap cytology examination.
In all we detected 6.4% (5/78) CIN2 or greater in this
small pilot cohort out of which 2 cases were CIS. Since
HIV-infected women have a significant hazard of pro-
gression from CIN to ICC [5], our data suggests that in
situations where facilities for colposcopic examination
are limited, efforts should be focused on conducting
early colposcopic examination of HIV-infected women with
NCC who are over 30 years and positive HR-HPV. We
need to study a larger cohort with a longer follow up time,
across different regions in Nigeria including HIV positive
and negative women to have better insights on the optimal
approach for managing HIV infected women with NCC in
our setting.
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